BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22147076)

  • 1. Going past the data for temozolomide.
    Villano JL; Letarte N; Bressler LR
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1113-5. PubMed ID: 22147076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
    Stupp R; Hegi ME; Mason WP; van den Bent MJ; Taphoorn MJ; Janzer RC; Ludwin SK; Allgeier A; Fisher B; Belanger K; Hau P; Brandes AA; Gijtenbeek J; Marosi C; Vecht CJ; Mokhtari K; Wesseling P; Villa S; Eisenhauer E; Gorlia T; Weller M; Lacombe D; Cairncross JG; Mirimanoff RO; ;
    Lancet Oncol; 2009 May; 10(5):459-66. PubMed ID: 19269895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of chemoradiation for glioblastoma: a modern success story.
    Mirimanoff RO
    Curr Oncol Rep; 2006 Jan; 8(1):50-3. PubMed ID: 16464403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466).
    Linz U
    Cancer; 2010 Apr; 116(8):1844-6. PubMed ID: 20151424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.
    Mirimanoff RO; Gorlia T; Mason W; Van den Bent MJ; Kortmann RD; Fisher B; Reni M; Brandes AA; Curschmann J; Villa S; Cairncross G; Allgeier A; Lacombe D; Stupp R
    J Clin Oncol; 2006 Jun; 24(16):2563-9. PubMed ID: 16735709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
    Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
    Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Temozolomide in patients with a glioblastoma multiforme: new developments].
    Bromberg JE; Postma TJ
    Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1376-8. PubMed ID: 15997689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma.
    Hamilton DA
    Cancer Treat Rev; 2006 Oct; 32(6):483-6. PubMed ID: 16730911
    [No Abstract]   [Full Text] [Related]  

  • 9. [Standards and new developments in the chemotherapy of glioblastomas].
    Weller M
    Dtsch Med Wochenschr; 2005 Oct; 130(40):2270-4. PubMed ID: 16208603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy for malignant gliomas.
    Marosi C
    Wien Med Wochenschr; 2006 Jun; 156(11-12):346-50. PubMed ID: 16944366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant temozolomide: how long and how much?
    Franceschi E; Tosoni A; Brandes AA
    Expert Rev Anticancer Ther; 2008 May; 8(5):663-5. PubMed ID: 18471038
    [No Abstract]   [Full Text] [Related]  

  • 12. Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study.
    Sridhar T; Gore A; Boiangiu I; Machin D; Symonds RP
    Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):19-22. PubMed ID: 18838255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review.
    Ataman F; Poortmans P; Stupp R; Fisher B; Mirimanoff RO
    Eur J Cancer; 2004 Jul; 40(11):1724-30. PubMed ID: 15251162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Status quo--standard-of-care medical and radiation therapy for glioblastoma.
    Becker KP; Yu J
    Cancer J; 2012; 18(1):12-9. PubMed ID: 22290252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide in glioblastoma multiforme of the elderly.
    Brandes AA; Vastola F; Basso U; Pasetto LM; Ermani M; Berti F; Rotilio A; Amistà P; Scienza R; Monfardini S
    Tumori; 2002; 88(1 Suppl 1):S69-70. PubMed ID: 11989929
    [No Abstract]   [Full Text] [Related]  

  • 17. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
    Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
    Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma].
    Malkoun N; Fotso MJ; Cartier L; Forest F; Auberdiac P; Chargari C; Thorin J; Pacaut C; Peoc'h M; Nuti C; Schmitt T; Magné N
    Cancer Radiother; 2011 Jun; 15(3):202-7. PubMed ID: 21450506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of brain tumors.
    Ashby L; LaRocca R; Ryken T
    N Engl J Med; 2005 Jun; 352(22):2350-3; author reply 2350-3. PubMed ID: 15938013
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment of brain tumors.
    Seiter K
    N Engl J Med; 2005 Jun; 352(22):2350-3; author reply 2350-3. PubMed ID: 15938012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.